New AHIP chief: Insurers are watching single-payer proposals closely

Matt Eyles will take over on June 1 as the new CEO of the health insurance industry’s largest lobbying group, America’s Health Insurance Plans (AHIP). Ahead of assuming the top post, he spoke with Vox about several major legislative trends which could impact insurers. 

Among the proposals he’s watching are Democrats’ push for single-payer healthcare. While groups representing hospitals and physician practices have been dismissive of those talks, Eyles said AHIP is “very mindful” of the greater acceptance of single-payer among some Democrats.

“We see obviously a lot of risk with that,” he said. “If you think of 180 million people who are covered by the employer market today, that would be enormously disruptive. If you think of all the people that are in Medicare, are they just going to be cut out of that, or what will happen to those in Medicaid?”

In a survey from Reaction Data released in August 2017, payers were more opposed to single-payer than providers or employer benefit managers.

Eyles’s more immediate concerns are a renewed push for repealing the Affordable Care Act (which he doubts will happen in 2018) and replacing the individual mandate with automatic enrollment in a basic insurance plan.

Read more at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.